Brady Collins
Hepatitis A is a liver infection caused by the hepatitis A virus (HAV). The first hepatitis A vaccine was approved in the European Union in 1991, and in the United States in 1995. Since universal childhood vaccination was recommended in 2006, hepatitis A cases in the U.S. have dropped by 95%. Hepatitis A vaccines are highly effective, long-lasting, and safe, and they have played a crucial role in controlling the spread of the disease.
| Characteristics | Values |
|---|---|
| First hepatitis A vaccine approved | 1991 (European Union) |
| Hepatitis A vaccine licensed in the US | 1995 |
| Hepatitis A vaccine phased in | 1996 |
| Hepatitis A vaccination recommended for | Children over one year of age, people whose sexual activity puts them at risk, people with chronic liver disease, people being treated with clotting factor concentrates, people working near the virus, people living in communities where an outbreak is present, travellers to places where the virus is common |
Explore related products
What You'll Learn
Hepatitis A vaccine was first licensed in the US in 1995
Hepatitis A is a vaccine-preventable virus, and the development of a vaccine has been a significant step in reducing the incidence of the disease. Hepatitis A vaccine was first licensed in the US in 1995.
Prior to the introduction of the vaccine, hygienic measures and passive protection with immune globulin (IG) were the primary methods used to prevent hepatitis A. Hepatitis A was the most frequently reported type of hepatitis in the United States before 2004. After the Hepatitis A vaccine was introduced in 1996, cases of hepatitis A decreased by over 95% by 2011. This success was short-lived, as the disease re-emerged in 2016 due to outbreaks among individuals experiencing homelessness and drug use.
The Hepatitis A vaccine is highly effective, with an efficacy rate of around 95%. It provides long-term protection against the hepatitis A virus (HAV) infection and is recommended for all children over one year of age. The vaccine is given in two doses, with the initial dose followed by a booster six to twelve months later. The vaccine is safe, and severe side effects are very rare.
The development of the Hepatitis A vaccine has been a global effort, with the first vaccine approved in the European Union in 1991 and worldwide use beginning in 1992. The World Health Organization (WHO) has recommended universal vaccination in areas where the disease is moderately common, and the goal of eliminating viral hepatitis by 2030 has been a driving force in increasing vaccine coverage.
Pneumonia Vaccine: Walking Pneumonia Protection?
You may want to see also
Explore related products
The vaccine is recommended for children over one year old
Hepatitis A vaccines were first licensed for use in the United States in 1995. These vaccines provide long-term protection against the hepatitis A virus (HAV) infection. The first hepatitis A vaccine was approved in the European Union in 1991.
The hepatitis A vaccine is recommended for children over one year old. The US Centers for Disease Control and Prevention (CDC) recommends vaccinating all children between the ages of 12 months and 23 months. The Advisory Committee on Immunization Practices (ACIP) has also recommended routine hepatitis A vaccination for children aged 12-23 months, regardless of risk category or location. This has resulted in a significant decrease in hepatitis A cases in the United States.
The hepatitis A vaccine is given as injections, or shots, which contain a small piece of the hepatitis A virus that's killed or inactivated. The body's immune system then creates proteins called antibodies, which can identify and fight the virus. These antibodies provide long-lasting immunity, which means that if the person is exposed to the hepatitis A virus, they will not get sick.
The hepatitis A vaccine is safe and effective, with mild and short-lived side effects such as soreness, redness, fever, headache, tiredness, or loss of appetite. It is important to note that there is a small risk of an allergic reaction, so parents should monitor their children after vaccination and consult a doctor if any symptoms of an allergic reaction occur.
In addition to children over one year old, the CDC also recommends the hepatitis A vaccine for people with specific risk factors, such as those with chronic liver disease, those who are sexually active, and those travelling to regions where hepatitis A is prevalent.
Antibodies: What They Don't Do and Why
You may want to see also
Explore related products
It is also recommended for those travelling to high-risk areas
Hepatitis A vaccines were first licensed for use in the United States in 1995. Since then, millions of doses have been administered, and cases of hepatitis A have declined significantly. However, outbreaks still occur, and certain groups remain at high risk for hepatitis A infection.
International travel is a significant risk factor for hepatitis A, and the US Centers for Disease Control and Prevention (CDC) recommends vaccination for all persons over six months of age travelling to regions with intermediate to high endemicity of hepatitis A. These areas include the Indian subcontinent, Africa, Central America, South America, Asia, and Eastern Europe. Vaccination is particularly crucial for travellers as hepatitis A is the most common vaccine-preventable virus acquired during travel.
The hepatitis A vaccine is typically given as a single initial injection, followed by a second dose six to twelve months later. This two-dose regimen provides long-term protection, with immunity lasting for at least twenty years, and possibly a lifetime. It is important to receive the initial dose at least two weeks before departure, although it can be administered up to the day of travel if necessary.
For travellers who are only partially vaccinated or have received their first dose within the past six months, a single dose before travel may be sufficient, according to the vaccine schedule. However, it is always advisable to consult a healthcare provider for specific recommendations and to ensure adequate protection before embarking on a trip to high-risk areas.
In addition to travellers, other high-risk groups for hepatitis A include men who have sex with men, people who use or inject drugs, people with chronic liver disease, and those experiencing homelessness. Vaccination is strongly recommended for these individuals to prevent infection and reduce the risk of severe complications from hepatitis A.
How Aminoglycosides Enhance Vaccine Efficacy
You may want to see also
Explore related products
The vaccine is given in two doses, six months apart
Hepatitis A vaccines were first licensed for use in the United States in 1995, though the first vaccine was approved in the European Union in 1991 and was first used worldwide in 1992. Since then, hepatitis A cases in the U.S. have decreased by over 95%.
The hepatitis A vaccine is highly effective, protecting against the virus in around 95% of cases for at least twenty years, and possibly a person's entire life. It is administered via injection into the muscle of the upper arm.
The hepatitis A vaccine is recommended for persons aged 6 months or older who are travelling to or working in countries where there is a high or intermediate endemicity of HAV infection. It is also recommended for children over one year of age, people with chronic liver disease, people who are being treated with clotting factor concentrates, people working near the virus, and people living in communities where an outbreak is present.
Combination Skin: What's True and False?
You may want to see also
Explore related products
Hepatitis A cases in the US decreased by 95% between 1996 and 2011
Hepatitis A is a liver infection caused by the hepatitis A virus (HAV). The Hepatitis A vaccine was first approved in the United States in 1995 and was phased in around 1996. Since the release of the first vaccine, the rate of new HAV infections in the United States declined by more than 95% from 1996 to 2011. The number of reported cases in the United States reached an all-time low in 2011, with 1398 cases, representing a 95.5% decline in reported cases since the first vaccine recommendation in 1996. The decline in hepatitis A cases can be attributed to the widespread adoption of the hepatitis A vaccine, which has been recommended for routine immunization of selected high-risk groups and children in the United States since the mid-1990s.
In 1996, the Advisory Committee for Immunization Practices (ACIP) recommended routine immunization for travellers to HAV-endemic countries, several other risk groups, and persons with chronic liver disease. The ACIP has played a crucial role in advising and revising vaccination recommendations over the years. In 1999, the ACIP expanded its recommendations to include immunizing all children over two years of age living in states or communities with higher-than-average HAV infection rates. This proactive approach ensured that those at a higher risk of exposure were prioritised for vaccination.
The effectiveness of the vaccine and its widespread administration have significantly reduced the overall number of hepatitis A cases. The incidence of HAV infection in the United States decreased substantially, from 10 cases per 100,000 population in 1996 to 0.4 cases per 100,000 population in 2011. This reduction in cases is a direct result of the vaccine's success, as hepatitis A was previously the most frequently reported type of hepatitis in the United States before the vaccine's introduction.
The decline in hepatitis A cases has had a positive impact on public health, particularly in reducing morbidity and mortality among children and adolescents. The average age of hepatitis A-related hospitalizations and deaths has increased, indicating that the vaccine is effectively protecting younger individuals from severe disease. Furthermore, universal childhood vaccination has contributed to this downward trend, as evidenced by the dramatic declines in reported hepatitis cases in other countries that have implemented routine childhood HAV immunizations.
While the vaccine has been highly successful, it's important to remain vigilant. Hepatitis A cases began to fluctuate from 2012 onwards, with an increase in reported cases in 2013 due to a multistate foodborne outbreak. From 2016 to 2020, person-to-person outbreaks contributed to over 33,000 infections, with high numbers of hospitalizations and deaths. These outbreaks highlight the ongoing need for vaccination and public health measures to prevent the spread of hepatitis A and protect vulnerable populations.
Yellow Fever Vaccine: Lifetime Immunity?
You may want to see also
Frequently asked questions
The Hepatitis A vaccine was first licensed in the US in 1995.
The first Hepatitis A vaccine was approved in the European Union in 1991 and in the US in 1995.
The Hepatitis A vaccine is recommended for persons aged 6 months or older. The World Health Organization (WHO) recommends universal vaccination in areas where the disease is moderately common.
Two doses of the Hepatitis A vaccine are recommended for the best protection.
The Hepatitis A vaccine is effective in around 95% of cases and lasts for at least 20 years and possibly a person's entire life.
